|
1
|
Miettinen M, Sobin LH and Lasota J:
Gastrointestinal stromal tumors of the stomach: A
clinicopathologic, immunohistochemical, and molecular genetic study
of 1765 cases with long-term follow-up. Am J Surg Pathol. 29:52–68.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huang RX, Xiang P and Huang C:
Gastrointestinal stromal tumors: Current translational research and
management modalities. Eur Rev Med Pharmacol Sci. 18:3076–3085.
2014.PubMed/NCBI
|
|
3
|
Dematteo RP, Heinrich MC, El-Rifai WM and
Demetri G: Clinical management of gastrointestinal stromal tumors:
Before and after STI-571. Hum Pathol. 33:466–477. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Corless CL, Barnett CM and Heinrich MC:
Gastrointestinal stromal tumours: Origin and molecular oncology.
Nat Rev Cancer. 11:865–878. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hirota S, Isozaki K, Moriyama Y, Hashimoto
K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M,
et al: Gain-of-function mutations of c-kit in human
gastrointestinal stromal tumors. Science. 279:577–580. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Heinrich MC, Corless CL, Duensing A,
McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A,
Town A, et al: PDGFRA activating mutations in gastrointestinal
stromal tumors. Science. 299:708–710. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lenkala D, LaCroix B, Gamazon ER, Geeleher
P, Im HK and Huang RS: The impact of microRNA expression on
cellular proliferation. Hum Genet. 133:931–938. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer. 96
Suppl:R40–R44. 2007.PubMed/NCBI
|
|
10
|
Shivdasani RA: MicroRNAs: regulators of
gene expression and cell differentiation. Blood. 108:3646–3653.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bueno MJ and Malumbres M: MicroRNAs and
the cell cycle. Biochim Biophys Acta. 1812:592–601. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tüfekci KU, Oner MG, Meuwissen RL and Genç
S: The role of microRNAs in human diseases. Methods Mol Biol.
1107:33–50. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hayes J, Peruzzi PP and Lawler S:
MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reddy KB: MicroRNA (miRNA) in cancer.
Cancer Cell Int. 15:382015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim WK, Yang HK and Kim H: MicroRNA
involvement in gastrointestinal stromal tumor tumorigenesis. Curr
Pharm Des. 1227–1235. 2013.PubMed/NCBI
|
|
16
|
Fan R, Zhong J, Zheng S, Wang Z, Xu Y, Li
S, Zhou J and Yuan F: MicroRNA-218 inhibits gastrointestinal
stromal tumor cell and invasion by targeting KIT. Tumour Biol.
35:4209–4217. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cao CL, Niu HJ, Kang SP, Cong CL and Kang
SR: miRNA-21 sensitizes gastrointestinal stromal tumors (GISTs)
cells to Imatinib via targeting B-cell lymphoma 2 (Bcl-2). Eur Rev
Med Pharmacol Sci. 20:3574–3581. 2016.PubMed/NCBI
|
|
18
|
Ihle MA, Trautmann M, Kuenstlinger H, Huss
S, Heydt C, Fassunke J, Wardelmann E, Bauer S, Schildhaus HU,
Buettner R, et al: miRNA-221 and miRNA-222 induce apoptosis via the
KIT/AKT signalling pathway in gastrointestinal stromal tumours. Mol
Oncol. 9:1421–1433. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim WK, Park M, Kim YK, Tae YK, Yang HK,
Lee JM and Kim H: MicroRNA-494 downregulates KIT and inhibits
gastrointestinal stromal tumor cell proliferation. Clin Cancer Res.
17:7584–7594. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Akçakaya P, Caramuta S, Åhlen J, Ghaderi
M, Berglund E, Östman A, Bränström R, Larsson C and Lui WO:
microRNA expression signatures of gastrointestinal stromal tumours:
Associations with imatinib resistance and patient outcome. Br J
Cancer. 111:2091–2102. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Akçakaya P and Lui WO: MicroRNAs and
gastrointestinal stromal tumor. Adv Exp Med Biol. 889:51–70. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Haller F, von Heydebreck A, Zhang JD,
Gunawan B, Langer C, Ramadori G, Wiemann S and Sahin O:
Localization- and mutation-dependent microRNA (miRNA) expression
signatures in gastrointestinal stromal tumours (GISTs), with a
cluster of co-expressed miRNAs located at 14q32.31. J Pathol.
220:71–86. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chiang CH, Hou MF and Hung WC:
Up-regulation of miR-182 by β-catenin in breast cancer increases
tumorigenicity and invasiveness by targeting the matrix
metalloproteinase inhibitor RECK. Biochim Biophys Acta.
1830:3067–3076. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tang T, Wong HK, Gu W, Yu MY, To KF, Wang
CC, Wong YF, Cheung TH, Chung TK and Choy KW: MicroRNA-182 plays an
onco-miRNA role in cervical cancer. Gynecol Oncol. 129:199–208.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guttilla IK and White BA: Coordinate
regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast
cancer cells. J Biol Chem. 284:23204–23216. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Segura MF, Hanniford D, Menendez S, Reavie
L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A,
Bogunovic D, et al: Aberrant miR-182 expression promotes melanoma
metastasis by repressing FOXO3 and microphthalmia-associated
transcription factor. Proc Natl Acad Sci USA. 106:1814–1819. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu Z, Liu J, Segura MF, Shao C, Lee P,
Gong Y, Hernando E and Wei JJ: MiR-182 overexpression in
tumourigenesis of high-grade serous ovarian carcinoma. J Pathol.
228:204–215. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Moskwa P, Buffa FM, Pan Y, Panchakshari R,
Gottipati P, Muschel RJ, Beech J, Kulshrestha R, Abdelmohsen K,
Weinstock DM, et al: miR-182-mediated downregulation of BRCA1
impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell.
41:210–220. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang L, Mao P, Song L, Wu J, Huang J, Lin
C, Yuan J, Qu L, Cheng SY and Li J: miR-182 as a prognostic marker
for glioma progression and patient survival. Am J Pathol.
177:29–38. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Song L, Liu L, Wu Z, Li Y, Ying Z, Lin C,
Wu J, Hu B, Cheng SY, Li M, et al: TGF-β induces miR-182 to sustain
NF-κB activation in glioma subsets. J Clin Invest. 122:3563–3578.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Massoumi R: CYLD: A deubiquitination
enzyme with multiple roles in cancer. Future Oncol. 7:285–297.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sun SC: CYLD: A tumor suppressor
deubiquitinase regulating NF-kappaB activation and diverse
biological processes. Cell Death Differ. 17:25–34. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hayashi M, Jono H, Shinriki S, Nakamura T,
Guo J, Sueta A, Tomiguchi M, Fujiwara S, Yamamoto-Ibusuki M,
Murakami K, et al: Clinical significance of CYLD downregulation in
breast cancer. Breast Cancer Res Treat. 143:447–457. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Deng LL, Shao YX, Lv HF, Deng HB and Lv
FZ: Over-expressing CYLD augments antitumor activity of TRAIL by
inhibiting the NF-κB survival signaling in lung cancer cells.
Neoplasma. 59:18–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Courtois G: Tumor suppressor CYLD:
Negative regulation of NF-kappaB signaling and more. Cell Mol Life
Sci. 65:1123–1132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Oeckinghaus A and Ghosh S: The NF-kappaB
family of transcription factors and its regulation. Cold Spring
Harb Perspect Biol. 1:a0000342009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Calin GA and Croce CM: MicroRNA-cancer
connection: The beginning of a new tale. Cancer Res. 66:7390–7394.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cheng CJ and Slack FJ: The duality of
oncomiR addiction in the maintenance and treatment of cancer.
Cancer J. 18:232–237. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kasinski AL and Slack FJ: Epigenetics and
genetics. MicroRNAs en route to the clinic: Progress in validating
and targeting microRNAs for cancer therapy. Nat Rev Cancer.
11:849–864. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wei Q, Lei R and Hu G: Roles of miR-182 in
sensory organ development and cancer. Thorac Cancer. 6:2–9. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hanke M, Hoefig K, Merz H, Feller AC,
Kausch I, Jocham D, Warnecke JM and Sczakiel G: A robust
methodology to study urine microRNA as tumor marker: microRNA-126
and microRNA-182 are related to urinary bladder cancer. Urol Oncol.
28:655–661. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang J, Li J, Shen J, Wang C, Yang L and
Zhang X: MicroRNA-182 downregulates metastasis suppressor 1 and
contributes to metastasis of hepatocellular carcinoma. BMC Cancer.
12:2272012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hirata H, Ueno K, Shahryari V, Deng G,
Tanaka Y, Tabatabai ZL, Hinoda Y and Dahiya R: MicroRNA-182-5p
promotes cell invasion and proliferation by down regulating FOXF2,
RECK and MTSS1 genes in human prostate cancer. PLoS One.
8:e555022013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lei R, Tang J, Zhuang X, Deng R, Li G, Yu
J, Liang Y, Xiao J, Wang HY, Yang Q, et al: Suppression of MIM by
microRNA-182 activates RhoA and promotes breast cancer metastasis.
Oncogene. 33:1287–1296. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yan D, Dong XD, Chen X, Yao S, Wang L,
Wang J, Wang C, Hu DN, Qu J and Tu L: Role of microRNA-182 in
posterior uveal melanoma: Regulation of tumor development through
MITF, BCL2 and cyclin D2. PLoS One. 7:e409672012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yang WB, Chen PH, Hsu T, Fu TF, Su WC,
Liaw H, Chang WC and Hung JJ: Sp1-mediated microRNA-182 expression
regulates lung cancer progression. Oncotarget. 5:740–753. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Rasheed SA, Teo CR, Beillard EJ, Voorhoeve
PM and Casey PJ: MicroRNA-182 and microRNA-200a control G-protein
subunit α-13 (GNA13) expression and cell invasion synergistically
in prostate cancer cells. J Biol Chem. 288:7986–7995. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yang MH, Yu J, Jiang DM, Li WL, Wang S and
Ding YQ: microRNA-182 targets special AT-rich sequence-binding
protein 2 to promote colorectal cancer proliferation and
metastasis. J Transl Med. 12:1092014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang YQ, Guo RD, Guo RM, Sheng W and Yin
LR: MicroRNA-182 promotes cell growth, invasion, and
chemoresistance by targeting programmed cell death 4 (PDCD4) in
human ovarian carcinomas. J Cell Biochem. 114:1464–1473. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Bowen S, Gill M, Lee DA, Fisher G,
Geronemus RG, Vazquez ME and Celebi JT: Mutations in the CYLD gene
in Brooke-Spiegler syndrome, familial cylindromatosis, and multiple
familial trichoepithelioma: Lack of genotype-phenotype correlation.
J Invest Dermatol. 124:919–920. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Bignell GR, Warren W, Seal S, Takahashi M,
Rapley E, Barfoot R, Green H, Brown C, Biggs PJ, Lakhani SR, et al:
Identification of the familial cylindromatosis tumour-suppressor
gene. Nat Genet. 25:160–165. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
54
|
Nikolaou K, Tsagaratou A, Eftychi C,
Kollias G, Mosialos G and Talianidis I: Inactivation of the
deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation,
fibrosis, and cancer. Cancer Cell. 21:738–750. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hellerbrand C, Bumes E, Bataille F,
Dietmaier W, Massoumi R and Bosserhoff AK: Reduced expression of
CYLD in human colon and hepatocellular carcinomas. Carcinogenesis.
28:21–27. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Gilmore TD: Introduction to NF-kappaB:
Players, pathways, perspectives. Oncogene. 25:6680–6684. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Schreck R, Albermann K and Baeuerle PA:
Nuclear factor kappa B: An oxidative stress-responsive
transcription factor of eukaryotic cells (a review). Free Radic Res
Commun. 17:221–237. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wang CY, Mayo MW and Baldwin AS Jr: TNF-
and cancer therapy-induced apoptosis: Potentiation by inhibition of
NF-kappaB. Science. 274:784–787. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Dolcet X, Llobet D, Pallares J and
Matias-Guiu X: NF-κB in development and progression of human
cancer. Virchows Arch. 446:475–482. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Xia Y, Shen S and Verma IM: NF-κB, an
active player in human cancers. Cancer Immunol Res. 2:823–830.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Karin M, Cao Y, Greten FR and Li ZW:
NF-kappaB in cancer: From innocent bystander to major culprit. Nat
Rev Cancer. 2:301–310. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
62
|
Jovanovic M and Hengartner MO: miRNAs and
apoptosis: RNAs to die for. Oncogene. 25:6176–6187. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Lima RT, Busacca S, Almeida GM, Gaudino G,
Fennell DA and Vasconcelos MH: MicroRNA regulation of core
apoptosis pathways in cancer. Eur J Cancer. 47:163–174. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Pileczki V, Cojocneanu-Petric R, Maralani
M, Neagoe IB and Sandulescu R: MicroRNAs as regulators of apoptosis
mechanisms in cancer. Clujul Med. 89:50–55. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Subramanian S and Steer CJ: MicroRNAs as
gatekeepers of apoptosis. J Cell Physiol. 223:289–298.
2010.PubMed/NCBI
|
|
66
|
Wang HL, Zhou R, Liu J, Chang Y, Liu S,
Wang XB, Huang MF and Zhao Q: MicroRNA-196b inhibits late apoptosis
of pancreatic cancer cells by targeting CADM1. Sci Rep.
7:114672017. View Article : Google Scholar : PubMed/NCBI
|
